an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age

Study Design

To describe the effect of a single dose of mRNA-1345 vaccine on the number of participants with first episode of RSV-LRTD by baseline comorbidities such as COPD, asthma, any chronic respiratory or pulmonary disease, diabetes mellitus type 1 or 2, CHF, and advanced liver or renal disease.

CLINICAL STUDY PROTOCOL

See If You're Eligible

Purpose of Study

Primary

Secondary

Participation

Benefits of Study Participation

Contact Us